288 filings
Page 5 of 15
8-K
azwqusx5 mavzi
12 Apr 21
Regulation FD Disclosure
7:40am
S-8
yl1an xw7z5cyw3
17 Feb 21
Registration of securities for employees
4:50pm
8-K
ddx63j3s1bnbfzvu
17 Feb 21
Blueprint Medicines Reports Fourth Quarter and Full Year 2020 Financial Results
8:00am
UPLOAD
fs5 uyvkfqt
11 Feb 21
Letter from SEC
12:00am
CORRESP
cj4 ijulrnz6
14 Jan 21
Correspondence with SEC
12:00am
8-K
tpeyss tdo
11 Jan 21
Entry into a Material Definitive Agreement
8:20am
8-K
3epg0o4mnumly6h89
17 Dec 20
Other Events
4:15pm
UPLOAD
81bhxu7aib
2 Dec 20
Letter from SEC
12:00am
8-K
j9c31
1 Dec 20
Other Events
4:23pm
8-K
xx6wn
29 Oct 20
Blueprint Medicines Reports Third Quarter 2020 Financial Results
8:00am
8-K
9vfowe3 gppmf2z7
22 Sep 20
Regulation FD Disclosure
8:20am
8-K
3z00aan
21 Sep 20
Other Events
8:00am
8-K
o12ix
8 Sep 20
Blueprint Medicines Announces FDA Approval of GAVRETO™ (pralsetinib) for the Treatment
6:03am
8-K
w336lkj
1 Sep 20
Blueprint Medicines Strengthens Leadership with Appointment of Fouad Namouni, M.D., as President, Research & Development
8:28am
424B5
yn8h 3p9amjabji
31 Jul 20
Prospectus supplement for primary offering
4:00pm
8-K
d8dfual
30 Jul 20
Blueprint Medicines Reports Second Quarter 2020 Financial Results
7:38am